Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.

[1]  F. Dazzi,et al.  Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? , 2013, Immunology and cell biology.

[2]  D. Campana,et al.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. , 2012, Blood.

[3]  D. Greco,et al.  Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. , 2012, Experimental hematology.

[4]  P. Virdis,et al.  Patients with Early-Stage Myelodysplastic Syndromes Show Increased Frequency of CD4+CD25high+CD127low Regulatory T Cells , 2012, Acta Haematologica.

[5]  K. Rezvani,et al.  Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. , 2012, Blood.

[6]  D. Marin,et al.  KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib , 2012, Leukemia.

[7]  C. Carcassi,et al.  Interactions between killer immunoglobulin‐like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm , 2012, British journal of haematology.

[8]  G. Polat,et al.  Killer cell immunoglobulin-like receptor genes in patients with breast cancer , 2012, Medical Oncology.

[9]  F. Bertucci,et al.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. , 2011, The Journal of clinical investigation.

[10]  P. Validire,et al.  Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. , 2011, Cancer research.

[11]  D. Middleton,et al.  Increased killer immunoglobulin‐like receptor expression and functional defects in natural killer cells in lung cancer , 2011, Immunology.

[12]  F. Locatelli,et al.  Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. , 2011, Blood.

[13]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[14]  H. Salih,et al.  The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity , 2010, International journal of cancer.

[15]  D. Middleton,et al.  Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. , 2010, Human immunology.

[16]  K. Campbell,et al.  [Natural killer cells and cancer. Regulation by the killer cell Ig-like receptors (KIR)]. , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[17]  Derek Middleton,et al.  The extensive polymorphism of KIR genes , 2010, Immunology.

[18]  S. Negrini,et al.  Soluble HLA‐I‐mediated secretion of TGF‐β1 by human NK cells and consequent down‐regulation of anti‐tumor cytolytic activity , 2009, European journal of immunology.

[19]  Simona Soverini,et al.  Response definitions and European Leukemianet Management recommendations. , 2009, Best practice & research. Clinical haematology.

[20]  J. Goldman Treatment strategies for CML. , 2009, Best practice & research. Clinical haematology.

[21]  A. Daneri-Navarro,et al.  Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions , 2009, BMC Cancer.

[22]  P. Gourraud,et al.  Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. , 2009, Tissue antigens.

[23]  K. Kärre Natural killer cell recognition of missing self , 2008, Nature Immunology.

[24]  P. Parham,et al.  Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL31 , 2008, The Journal of Immunology.

[25]  G. Altavilla,et al.  Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells , 2008, Cancer.

[26]  D. Marin,et al.  Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy , 2007, Leukemia.

[27]  P. Parham,et al.  Functional Polymorphism of the KIR3DL1/S1 Receptor on Human NK Cells1 , 2007, The Journal of Immunology.

[28]  C. Carcassi,et al.  Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population , 2006, Journal of Translational Medicine.

[29]  M. Carrington,et al.  The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. , 2006, Annual review of genomics and human genetics.

[30]  J. Goldman,et al.  Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? , 2006, Leukemia & lymphoma.

[31]  L. Rodrigo,et al.  Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. , 2005, Journal of Infectious Diseases.

[32]  Milena Ivanova,et al.  Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals , 2005, Cancer Immunology, Immunotherapy.

[33]  S Verheyden,et al.  Identification of natural killer cell receptor phenotypes associated with leukemia , 2004, Leukemia.

[34]  K. Hsu,et al.  The killer cell immunoglobulin‐like receptor (KIR) genomic region: gene‐order, haplotypes and allelic polymorphism , 2002, Immunological reviews.

[35]  P. Parham,et al.  Predominance of group AKIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression , 2002, Immunogenetics.

[36]  N. Schleinitz,et al.  Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. , 2002, Human immunology.